Bill
HF 4201
HF 4201lets hemp and cannabis licensees cross-license, expands licensing for lower-potency hemp edibles, and tightens labeling to show cannabinoid content, testing, and safety info
Purpose and scope
- HF 4201 modifies licensing provisions for cannabis and hemp-related businesses, updates labeling requirements for cannabinoid products and lower-potency hemp edibles, and clarifies the interaction between cannabis and hemp licensing. The bill amends several sections of Minnesota Statutes to reflect these changes.
Main objectives
- Expand and clarify licensing options for hemp products (lower-potency hemp edibles) and cannabis-related licenses.
- Require more detailed labeling and product information for cannabis, hemp-derived products, and lower-potency hemp edibles.
- Establish cross-licensing possibilities and limits between hemp and cannabis sectors.
- Introduce or adjust labeling for topical hemp products and medical cannabinoid products.
- Set out testing, safety, and consumer information requirements to improve product transparency and safety.
Key provisions and changes
1) Licensing for lower-potency hemp edibles (Sec. 1 and Sec. 7)
- A person, cooperative, or business may hold any combination of:
- Lower-potency hemp edibleManufacturer
- Lower-potency hemp edibleWholesaler
- Lower-potency hemp edibleRetailer licenses
- A license holder may also hold:
- A license to cultivate industrial hemp (per chapter 18K)
- Other licenses (e.g., food sales, tobacco, alcohol, etc.)
- A license holder may also hold a cannabis business license (cross-licensing allowed), removing a previous restriction that might have prohibited this.
- The framework explicitly allows combining lower-potency hemp licenses with other non-cannabis licenses.
2) Hemp license issuance and eligibility (Sec. 2)
- Eligibility for hemp licenses (general):
- Applicant must be 21+, complete application/renewal honestly, pay fees.
- Prohibition on transfer remains (licenses may not be transferred).
- Renewal is annual.
- The bill maintains a prohibition on license transfers and adds specifics around compliance and eligibility.
3) Labeling changes for cannabis and hemp-derived products (Sec. 3, Sec. 4, Sec. 5, Sec. 6, Sec. 7)
- General label requirements for cannabis flower and hemp-derived consumer products (Sec. 3, Sec. 4):
- Must include license information for the grower/cultivator and the product manufacturing entity.
- Net weight, batch number, cannabinoid profile, universal symbol for product type, testing verification, usage information, and other office-required statements.
- Some elements previously required (e.g., certain warnings) are revised to special-purpose labels and new wording.
- Medical cannabis labeling (Sec. 5):
- Adds patient name, date of birth (and caregiver/parent when applicable), and registry ID on medical products.
- Hemp-derived topical products (Sec. 6):
- New labeling requirements for all hemp topical products:
- Manufacturer contact details, testing lab information, net weight/volume, product type, cannabinoids per serving and total, ingredients, disclaimer about medical claims, and office-required statements.
- THC-containing topicals (per Sec. 6(b)):
- Adds THC per serving and total THC, universal symbol for THC, poison control information, and testing verification.
- Lower-potency hemp edibles labeling (Sec. 7):
- Requires labeling to include:
- Information about the cultivating hemp business (name, address, country/state or license number).
- Information about the manufacturing business for hemp concentrate or cannabinoids (name/address or license number).
- Net weight, batch number, serving size, cannabinoid profile per serving and total THC.
- Ingredient list, universal symbol, warning symbol (not for children), poison control info, testing verification, usage directions, and other required information.
- Provisions allow scannable barcodes to convey licensing information if active and accurate.
- If the product contains only non-intoxicating cannabinoids and no THC, the universal symbol requirement is waived.
4) Labeling of medical cannabis and special scenarios (Sec. 5)
- Adds patient-specific labeling requirements for medical cannabis and cannabinoid products, ensuring patient identity details are included where applicable.
5) Approved cannabinoids and THC limits (Sec. 8)
- Allowed cannabinoids:
- Generally permits cannabidiol (CBD) and cannabigerol (CBG) in products with the possibility of added cannabinoids if approved by the office.
- THC content:
- For products containing additional cannabinoids (beyond CBD/CBG), if included as hemp concentrate or naturally occurring in hemp parts, the total THC per package must not exceed 0.3%.
- Office discretion remains for approving other cannabinoids beyond CBD/CBG under non-intoxicating criteria.
Affected parties
- Hemp licensees: growers, manufacturers, wholesalers, retailers of lower-potency hemp edibles.
- Cannabis licensees: microbusinesses, mezzobusinesses, cultivators, manufacturers, retailers, and related entities that interact with hemp licensing.
- Medical cannabis patients and caregivers: labeling changes to include patient identifiers and caregiver information.
- Consumers: enhanced labeling and safety information, including cannabinoid profiles, testing status, and clear warnings.
Timeline and procedures
- The bill provides standard licensing terms (annual renewals, eligibility criteria) and labeling deadlines consistent with existing regulatory structures. Specific implementation dates are not stated in the summary, but as a 2025-2026 session bill, compliance would align with enacted effective dates upon passage and signing.
Overall impact
- Creates greater regulatory alignment between cannabis and hemp sectors, enabling cross-licensing while expanding labeling requirements to improve consumer transparency and safety.
- Strengthens consumer information around cannabinoid content, testing, and usage guidance.
- Introduces enhanced labeling for hemp edibles and topical products, including THC-specific disclosures for products containing THC.
- Balances industry flexibility with safety measures by requiring testing verification and office-approved statements.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
